中外製薬、大阪大学のアクテムラ https://www.aphp.fr/contenu/tocilizumab-improves-significantly-clinical-outcomes-patients-moderate-or-severe-covid-19 日本では年内承認を目指す https://www.nikkei.com/article/DGXMZO58417490T20C20A4TJ1000/

COVID-19

powerhouse63w のブックマーク 2020/04/29 17:16

<blockquote class="hatena-bookmark-comment"><a class="comment-info" href="https://b.hatena.ne.jp/entry/4684985895779094178/comment/powerhouse63w" data-user-id="powerhouse63w" data-entry-url="https://b.hatena.ne.jp/entry/s/www.afpbb.com/articles/-/3280914" data-original-href="https://www.afpbb.com/articles/-/3280914" data-entry-favicon="https://cdn-ak2.favicon.st-hatena.com/64?url=https%3A%2F%2Fwww.afpbb.com%2Farticles%2F-%2F3280914" data-user-icon="/users/powerhouse63w/profile.png">関節炎薬、新型コロナに「著しい」効果 仏研究</a><ul class="comment-tag" style="list-style: none; margin: 0px;"><li style="float: left">[<a href="https://b.hatena.ne.jp/q/COVID-19">COVID-19</a>]</li></ul><br><p style="clear: left">中外製薬、大阪大学のアクテムラ <a href="https://www.aphp.fr/contenu/tocilizumab-improves-significantly-clinical-outcomes-patients-moderate-or-severe-covid-19" target="_blank" rel="noopener nofollow">https://www.aphp.fr/contenu/tocilizumab-improves-significantly-clinical-outcomes-patients-moderate-or-severe-covid-19</a> 日本では年内承認を目指す <a href="https://www.nikkei.com/article/DGXMZO58417490T20C20A4TJ1000/" target="_blank" rel="noopener nofollow">https://www.nikkei.com/article/DGXMZO58417490T20C20A4TJ1000/</a></p><a class="datetime" href="https://b.hatena.ne.jp/powerhouse63w/20200429#bookmark-4684985895779094178"><span class="datetime-body">2020/04/29 17:16</span></a></blockquote><script src="https://b.st-hatena.com/js/comment-widget.js" charset="utf-8" async></script>

このブックマークにはスターがありません。
最初のスターをつけてみよう！